View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients WithPrimary Biliary CholangitisWith Inadequate Response or Intolerance to Ursodeoxycholic Acid
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study ELATIVE